Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Less than a month after announcing a $50 billion investment in its U.S. operations over the next five years, Swiss pharma ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...